PT-141 · 1mg/spray nasal · research use only
PT-141 dosage, from the bremelanotide literature.
PT-141 (bremelanotide) is a melanocortin-receptor agonist studied for its effect on sexual-response pathways, and unlike most research peptides it has a defined dose in the clinical record. This page lays out the milligram ranges and the as-needed timing reported in the literature, how that maps onto Titan's metered 1mg-per-spray nasal format, and the short ~2–3 hour half-life — framed as a research reference, not a human protocol or medical advice.
As-needed, not scheduled
PT-141 is unusual among research peptides in that the literature dose is event-driven rather than a standing daily or weekly schedule. The reference subcutaneous figure in the bremelanotide record is 1.75 mg taken roughly 45 minutes before anticipated activity, with onset typically modelled at 30–45 minutes. Frequency is capped in the literature — no more than one dose per 24 hours and a low monthly ceiling — because the melanocortin pathway response does not benefit from stacking doses.
View the nasal spray →How the nasal math works
Titan's PT-141 ships as a metered nasal spray delivering 1 mg per actuation from a 10mL bottle. Because each spray is a fixed 1 mg, there is no reconstitution or syringe draw — the per-spray figure is the dose unit. Researchers modelling the injectable 1.75 mg reference against an intranasal route account for the lower and more variable bioavailability of mucosal delivery, which is the main variable when comparing the two formats.
Nasal vs injection →Short half-life
Bremelanotide's half-life is short — reported at roughly 2 to 3 hours — which fits the as-needed, single-use research model rather than a steady-state schedule. The short half-life is also why the literature caps dosing at once per 24 hours: the compound clears well within a day, so there is no accumulation argument for redosing inside that window.
View the nasal spray →Mechanism sets the dose
PT-141 acts centrally on melanocortin receptors (chiefly MC4R) rather than on the vascular pathway targeted by PDE5 research compounds. Because the response is receptor-mediated in the central nervous system, the effective research dose is a single low-milligram amount per event — increasing the dose does not scale the response and raises the side-effect profile reported in the literature.
PT-141 research overview →Format and purity to confirm
Titan's PT-141 is a pre-mixed metered nasal spray (10mL, 1 mg/spray) with an HPLC main-peak result against a ≥99% internal purity target and mass-spec identity on a lot-matched release sheet. With a fixed per-spray dose, the documentation is what confirms the metered figure is accurate — the spray mechanism removes draw-volume error but not the need to verify identity and concentration.
See the testing workflow →Research-use framing
While bremelanotide exists as an approved therapeutic in some jurisdictions, Titan supplies PT-141 strictly as a research-use-only reagent and the figures here are reproduced as a laboratory reference — not instructions for human use. Nothing on this page is medical or dosing advice; the compound is not for human or animal consumption.
Research-use policy →The detail, in plain terms
The dosing reference, in one table.
PT-141 dosing is event-driven and single-use, with a defined reference figure in the bremelanotide record. These are the variables a research protocol actually weighs — reproduced as a reference, not a human protocol.
- Compound
- PT-141 (bremelanotide) — melanocortin-receptor (MC4R) agonist.
- Reference dose
- 1.75 mg subcutaneous reference; taken as-needed, not scheduled.
- Timing
- ≈45 minutes before activity; onset modelled at 30–45 minutes.
- Frequency cap
- No more than once per 24 h; low monthly ceiling in the literature.
- Half-life
- Short — roughly 2 to 3 hours.
- Format
- Nasal spray, 10mL, 1 mg/spray, $69.99 — no reconstitution needed.
Questions researchers ask
Before you order.
- What is the research dosage for PT-141?
- The reference figure in the bremelanotide record is 1.75 mg subcutaneous, taken as-needed roughly 45 minutes before anticipated activity rather than on a standing schedule. Titan's nasal format delivers a fixed 1 mg per spray. These figures are reproduced as a laboratory research reference, not a human dosing protocol or medical advice.
- How is PT-141 dosing different for the nasal spray?
- Titan's PT-141 nasal spray delivers a metered 1 mg per actuation, so there is no reconstitution or syringe draw — the per-spray figure is the dose unit. Researchers comparing the intranasal route to the 1.75 mg injectable reference account for the lower and more variable bioavailability of mucosal absorption, which is the main difference between the two formats.
- How often can PT-141 be dosed in research?
- The literature caps PT-141 at no more than one dose per 24 hours, with a low monthly ceiling. Because the response is melanocortin-receptor mediated and the half-life is only a few hours, there is no accumulation rationale for redosing within a day and higher frequency raises the reported side-effect profile rather than the effect.
- What is PT-141's half-life?
- Bremelanotide's half-life is short — reported at roughly 2 to 3 hours. That fits the as-needed, single-use research model and is why the dosing literature treats it as an event-driven compound rather than a steady-state scheduled one.
- Is PT-141 approved for human use?
- Bremelanotide exists as an approved therapeutic in some jurisdictions, but Titan Peptide Lab supplies PT-141 strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use. Nothing on this page is medical or dosing advice.